HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
企業コードHCM
会社名HUTCHMED (China) Ltd
上場日May 19, 2006
最高経営責任者「CEO」Dr. Weiguo Su, Ph.D.
従業員数1811
証券種類Ordinary Share
決算期末May 19
本社所在地48th Floor, Cheung Kong Center, 2 Queen's Road Central
都市
証券取引所Hochiminh Stock Exchange
国Hong Kong
郵便番号- -
電話番号85221281188
ウェブサイトhttps://www.hutch-med.com/
企業コードHCM
上場日May 19, 2006
最高経営責任者「CEO」Dr. Weiguo Su, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし